DexCom had its Relative Strength (RS) Rating upgraded from 69 to 72 Monday — a welcome improvement, but still short of the 80 or better score you prefer to see.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an RS Rating of at least 80 as they begin their largest runs. See if DexCom can continue to show renewed price strength and clear that threshold.
DexCom broke out earlier, but has fallen back below the prior 87.65 entry from a cup with handle. In the scenario where a stock breaks out then falls 7% or more below the entry price, it's considered a failed breakout. If that happens, it's best to wait for a new pattern to form. Also keep in mind that the most recent consolidation is a later-stage base, and those involve more risk.
Top and bottom line growth moved higher last quarter. Earnings were up 0%, compared to -10% in the prior report. Revenue increased from 8% to 12%.
DexCom holds the No. 18 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and TransMedics Group are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
